Minerva Neurosciences, Inc. (NERV) |
|
2.36 0.15 (6.79%)
|
01-27 16:00 |
|
Open: |
2.24 |
Pre. Close: |
2.21 |
|
High:
|
2.44 |
Low:
|
2.22 |
|
Volume:
|
48,349 |
Market Cap:
|
13(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:46:33 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 3.49 One year: 4.07 |
| Support: |
Support1: 1.92 Support2: 1.25 |
| Resistance: |
Resistance1: 2.99 Resistance2: 3.49 |
| Pivot: |
2.07 |
| Moving Average: |
MA(5): 2.26 MA(20): 1.94
MA(100): 4.86  MA(250): 4.72 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 48.7 %D(3): 49.7 |
| RSI: |
RSI(14): 52.4 |
| 52-week: |
High: 15.27 Low: 0.36 |
| Average Vol(K): |
3-Month: 166 (K) 10-Days: 80 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NERV ] has closed below upper band by 16.8%. Bollinger Bands are 79.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 56 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.44 - 2.45 |
2.45 - 2.46 |
|
Low:
|
2.2 - 2.21 |
2.21 - 2.22 |
|
Close:
|
2.34 - 2.36 |
2.36 - 2.38 |
|
Company Description |
|
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. |
Headline News |
Fri, 27 Jan 2023
Minerva Neurosciences Inc (NERV) is higher by 4.07% Friday In Premarket Trading - InvestorsObserver
Thu, 26 Jan 2023
Neon Genesis Evangelion Is Ready to Release Its Soundtracks ... - ComicBook.com
Mon, 23 Jan 2023
Best Anime on Netflix According to Rotten Tomatoes and IMDb - What's on Netflix
Wed, 11 Jan 2023
Healthcare Stocks Making Moves Wednesday: TPST, NERV, NOTV, HOWL, KALA, PRE, PHVS, CANF - InvestorsObserver
Wed, 28 Dec 2022
Is it Time to Dump Minerva Neurosciences Inc (NERV) Stock After it Is Down 45.26% in a Week? - InvestorsObserver
Wed, 09 Nov 2022
Minerva Neurosciences, Inc. (NERV) Q3 2022 Earnings Call Transcript - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
5 (M) |
| Shares Float |
5 (M) |
|
% Held by Insiders
|
3.4 (%) |
|
% Held by Institutions
|
38.5 (%) |
|
Shares Short
|
197 (K) |
|
Shares Short P.Month
|
249 (K) |
Stock Financials |
|
EPS
|
-1.2 |
|
EPS Est Next Qtl
|
-0.34 |
|
EPS Est This Year
|
-0.9 |
|
EPS Est Next Year
|
-1.35 |
|
Book Value (p.s.)
|
-2.68 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-21 |
|
Return on Equity (ttm)
|
-675.1 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-3.16 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-4.94 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-25 (M) |
|
Levered Free Cash Flow
|
-20 (M) |
Stock Valuations |
|
PE Ratio
|
-1.98 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-0.89 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.5 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
